The Ministry of Health has published EBOLA DRC - Evolution of the response to the Ebola outbreak in the provinces of North Kivu and Ituri on Saturday, May 4, 2019. Excerpt from the Google translation:
EPIDEMIOLOGICAL SITUATION IN THE PROVINCES OF NORTH KIVU AND ITURI
Saturday, May 4, 2019
The epidemiological situation of the Ebola Virus Disease dated May 3, 2019:
• Since the beginning of the epidemic, the cumulative number of cases is 1,545, of which 1,479 are confirmed and 66 are probable. In total, there were 1,019 deaths (953 confirmed and 66 probable) and 434 people healed.
• Data not available for suspected cases;
• 16 new confirmed cases, including 6 in Katwa, 3 in Musienene, 2 in Mabalako, 2 in Mandima; 2 in Butembo and 1 in Vuhovi;
• 11 new confirmed case deaths, including
º 5 community / hospital deaths including 3 in Katwa, 1 in Mabalako and 1 in Mandima;
º 6 deaths at CTE / CT, including 3 in Butembo, 2 in Mabalako and 1 in Beni;
• 12 new healed from the CTE, including 4 in Katwa, 4 in Butembo, 3 in Beni and 1 in Mandima.
/! \ The data presented in this table are subject to change later, after extensive investigations and after redistribution of cases and deaths in their health areas.
News of the response
Vaccination
• Since the beginning of vaccination on 8 August 2018, 111,409 persons have been vaccinated , of which 30,432 in Katwa, 23,461 in Beni, 13,803 in Butembo, 7,093 in Mabalako, 4,901 in Mandima, 3,608 in Kalunguta, 3,070 in Goma, 2,879 in Komanda, 2,569 at Oicha, 1,930 at Masereka, 1,915 at Vuhovi, 1,810 at Kayna, 1,748 at Kyondo, 1,487 at Bunia, 1,372 at Lubero, 1,357 at Karisimbi, 1,197 at Musienene, 1,025 at Biena, 1,012 at Mutwanga, 690 at Rutshuru, 557 in Rwampara (Ituri), 527 in Nyankunde, 496 in Mangurujipa, 420 in Mambasa, 355 in Tchomia, 342 in Kirotshe, 333 in Lolwa, 254 in Alimbongo, 250 in Mweso, 245 in Kibirizi, 161 in Nyiragongo, 97 in Watsa (Haut-Uélé) and 13 in Kisangani.
• The only vaccine to be used in this outbreak is the rVSV-ZEBOV vaccine, manufactured by the pharmaceutical group Merck, following approval by the Ethics Committee in its decision of 19 May 2018.
